PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCandesartan cilexetil
Candesartan cilexetil
Atacand, Candesartan Cilexetil (candesartan cilexetil) is a small molecule pharmaceutical. Candesartan cilexetil was first approved as Atacand on 1998-06-04. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Atacand, Candesartan cilexetil (discontinued: Candesartan cilexetil)
Combinations
Atacand, Candesartan cilexetil hydrochlorothiazide (discontinued: Candesartan cilexetil hydrochlorothiazide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Candesartan cilexetil
Tradename
Company
Number
Date
Products
ATACANDANI PharmaceuticalsN-020838 RX1998-06-04
4 products, RLD, RS
Candesartan cilexetil
+
Hydrochlorothiazide
Tradename
Company
Number
Date
Products
ATACAND HCTANI PharmaceuticalsN-021093 RX2000-09-05
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
atacandNew Drug Application2020-06-19
atacand hctNew Drug Application2020-05-07
candesartanANDA2025-01-16
candesartan cilexetilNDA authorized generic2024-10-14
candesartan cilexetil and hydrochlorothiazideANDA2024-11-11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C09: Agents acting on the renin-angiotensin system
C09C: Angiotensin ii receptor blockers (arbs), plain
C09CA: Angiotensin ii receptor blockers (arbs), plain
C09CA06: Candesartan
C09D: Angiotensin ii receptor blockers (arbs), combinations
C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
C09DA06: Candesartan and diuretics
C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
C09DB07: Candesartan and amlodipine
C09DX: Angiotensin ii receptor blockers (arbs), other combinations
C09DX06: Candesartan, amlodipine and hydrochlorothiazide
HCPCS
No data
Clinical
Clinical Trials
200 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I101512272722103
Essential hypertensionD000075222I1027102526
Heart failureD006333EFO_0003144I50167418
Healthy volunteers/patients111214
Cardiovascular diseasesD002318EFO_0000319I981144313
Kidney diseasesD007674EFO_0003086N08115310
Covid-19D000086382U07.124218
ObesityD009765EFO_0001073E66.911417
Chronic renal insufficiencyD051436N181427
StrokeD020521EFO_0000712I63.9156
Show 33 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HeadacheD006261R51123
Cognitive dysfunctionD060825G31.8433
PheochromocytomaD01067311
Peripheral nervous system diseasesD010523G6411
Alzheimer diseaseD000544EFO_0000249F0311
Cocaine-related disordersD019970F1411
Cardio-renal syndromeD059347111
Liver diseasesD008107EFO_0001421K70-K77111
Alcoholic liver diseasesD008108EFO_0008573K70111
Hepatitis cD006526B19.211
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bipolar disorderD001714EFO_0000289F30.911
Therapeutic equivalencyD01381011
Barrett esophagusD001471EFO_0000280K22.711
HyperphosphatemiaD05455911
Substance-related disordersD019966EFO_0003890F1311
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCandesartan cilexetil
INN
Description
Candesartan is a benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an environmental contaminant and a xenobiotic. It is a benzimidazolecarboxylic acid and a biphenylyltetrazole. It is a conjugate acid of a candesartan(2-).
Classification
Small molecule
Drug classangiotensin II receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
Identifiers
PDB
CAS-ID139481-59-7
RxCUI214354
ChEMBL IDCHEMBL1014
ChEBI ID3348
PubChem CID2541
DrugBankDB13919
UNII ID
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Atacand AstraZeneca
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,353 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atacand, Atacand hct, Candesartan, Candesartan cilexetil
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
25,515 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use